文献速递消化、代谢与肾脏急症儿科与产科急症

镰状细胞病急性并发症相关疼痛的院前管理:一项初步的全国性横断面研究

Prehospital management of pain associated with acute complications of Sickle Cell Disease: a preliminary nationwide cross-sectional study.
PubMed 文献 · Am J Emerg Med · 2026-09-10
一句话结论美国2023年全国EMS数据:镰状细胞病并发症出车中仅13.5%给予任何镇痛,疼痛评分≥7分且接触时间≥20分钟者镇痛率约高10倍。

该研究为2023年美国全国9-1-1高级生命支持出车的横断面分析,纳入EMS临床印象为镰状细胞病并发症的10,023次出车。仅73.0%记录了疼痛评分,13.5%给予任何镇痛(阿片类11.7%),纳洛酮使用<0.1%。在疼痛评分≥7/10的患者中,EMS-患者接触时间≥20分钟者建立静脉通路约高5倍、接受任何镇痛或阿片类约高10倍。结论认为镰状细胞病相关疼痛的院前镇痛率低,尤其在接触时间短的出车中,改善空间大,或可通过鼻内镇痛实现。

要点

  • 在10,023次镰状细胞病并发症EMS出车中,仅13.5%给予任何镇痛,阿片类仅11.7%,纳洛酮使用<0.1%。
  • 疼痛评分记录率仅73.0%,提示院前疼痛评估不完整。
  • 疼痛评分≥7/10且EMS-患者接触时间≥20分钟者,建立静脉通路约高5倍、接受任何镇痛或阿片类约高10倍。
  • 5.2%为儿科患者,48.6%为女性,94.2%发生在城市环境,中位接触时间22.2分钟(IQR 15.4-31.0)。
  • 作者提出鼻内镇痛可能是改善院前镰状细胞病疼痛管理的途径,但原文未给出具体药物或剂量。

适用人群与场景

  • 2023年美国全国9-1-1高级生命支持出车中,EMS临床印象为镰状细胞病并发症的患者,包括成人及儿科(5.2%为儿科),94.2%为城市环境。

诊断标准与关键阈值

  • EMS临床印象为镰状细胞病并发症。
  • 疼痛评分采用数字评分法(原文为pain scale ≥7/10),原文未提及其他诊断标准或阈值。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值;仅报告任何镇痛给药率13.5%、阿片类11.7%、纳洛酮<0.1%。
  • 在疼痛评分≥7/10且接触时间≥20分钟的出车中,更常建立静脉通路并给予镇痛或阿片类;作者提出鼻内镇痛可能是改善方向,但原文未给出具体方案。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:全国性横断面分析;样本量:10,023次EMS出车;数据来源:2023年美国全国9-1-1高级生命支持出车样本。
  • 人群特征:5.2%儿科,48.6%女性,94.2%城市,中位接触时间22.2分钟(IQR 15.4-31.0)。
  • 主要结果:疼痛评分记录率73.0%;任何镇痛13.5%;阿片类11.7%;纳洛酮<0.1%。
  • 亚组结果:疼痛评分≥7/10且接触时间≥20分钟者,建立静脉通路约高5倍、接受任何镇痛或阿片类约高10倍。

证据类型、等级与局限

  • 证据类型:全国性横断面研究(初步研究);原文未给出证据等级或推荐强度。
  • 局限:横断面设计仅能描述关联不能推断因果;原文未提及单中心、回顾性等局限,但设计本身为观察性研究。

对床旁实践的改变

  • 提示院前镰状细胞病相关疼痛的镇痛率低,尤其接触时间短的出车中;对疼痛评分≥7/10的患者,延长接触时间与更积极的镇痛和静脉通路建立相关。
  • 适用人群为EMS临床印象为镰状细胞病并发症的患者;原文未提及不适用人群。
  • 常见陷阱:原文未提及。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: We aimed to describe the epidemiology of emergency medical services (EMS) encounters for sickle cell disease (SCD) complications, assess clinical practice patterns, and evaluate factors that may be associated with analgesia administration for SCD-related pain throughout the US.

METHODS: We completed a cross-sectional analysis using a nationwide sample of 9-1-1 advanced life support encounters during 2023 where the EMS clinician impression indicated complications of sickle cell disease. Outcomes of interest included pain scale measurements, pain management, and naloxone administration. Descriptive statistics were computed and stratified by key patient- and encounter-related factors.

RESULTS: Among a total of 10,023 EMS encounters for SCD complications, 5.2% were pediatric, 48.6% were female, and 94.2% took place in urban settings. Median patient contact time was 22.2 min (IQR: 15.4-31.0). Pain scale measurements were documented in 73.0% of encounters and analgesia of any kind was administered in 13.5% of cases, including opioids in 11.7%. Naloxone administration was rare (<0.1%). Among patients whose pain scale was ≥7/10, encounters where patient contact lasted 20 min or greater had intravenous access established nearly five-times more often and received any analgesia or opioids roughly ten-times more often.

CONCLUSIONS: In this large nationwide sample of EMS encounters for SCD complications, we found that administration of analgesia occurred more often during encounters with longer EMS-patient contact. However, low rates of pain control in all cases leaves room for improvement in EMS management of SCD-related pain, perhaps via intranasal analgesia.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Peters GA, Rapaport S, Fonjungo A, et al. Prehospital management of pain associated with acute complications of Sickle Cell Disease: a preliminary nationwide cross-sectional study. Am J Emerg Med. 2026. PMID: 42748533. doi:10.1016/j.ajem.2026.09.020

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。